First National Trust Co Cuts Stock Position in Kenvue Inc. $KVUE

First National Trust Co cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 68.0% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 18,417 shares of the company’s stock after selling 39,159 shares during the period. First National Trust Co’s holdings in Kenvue were worth $299,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of KVUE. Cornerstone Planning Group LLC lifted its stake in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after buying an additional 1,361 shares in the last quarter. NBT Bank N A NY raised its holdings in shares of Kenvue by 180.3% during the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after acquiring an additional 1,006 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in shares of Kenvue in the third quarter valued at approximately $25,000. Golden State Wealth Management LLC boosted its stake in shares of Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after acquiring an additional 1,190 shares during the last quarter. Finally, Trust Co. of Vermont increased its position in shares of Kenvue by 50.9% during the third quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock worth $39,000 after purchasing an additional 804 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Transactions at Kenvue

In other news, Director Jeffrey C. Smith bought 3,200,000 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the acquisition, the director directly owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. The trade was a 13.27% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 1.68% of the stock is currently owned by insiders.

Kenvue Trading Up 1.0%

KVUE opened at $18.50 on Thursday. The stock has a market capitalization of $35.44 billion, a PE ratio of 24.67 and a beta of 0.59. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The business’s 50 day moving average price is $17.32 and its 200 day moving average price is $17.78.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be given a dividend of $0.2075 per share. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Canaccord Genuity Group reissued a “hold” rating and issued a $15.00 price target (down from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. Johnson Rice reaffirmed a “neutral” rating on shares of Kenvue in a research note on Tuesday, October 28th. Evercore set a $18.00 price objective on shares of Kenvue in a report on Tuesday, October 28th. Finally, Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Four investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $19.46.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.